Cyclosporine Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg/mL
Reference Brands: Sandimmune (USA)
Category:
Transplant
This injection contains Cyclosporin which is an immunosuppressive agents. Immunosuppressive agents are the drugs that suppress or reduces the strength of our immune system.
CYCLOSPORINE INJECTION is available in Injection
and strengths such as 50 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, CYCLOSPORINE INJECTION is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
CYCLOSPORINE INJECTION can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
This injection is used in preventing organ rejection in patients who have had an organ transplant, bone marrow and stem cell transplantation.
Cyclosporine is a potent immunosuppressive agent widely used to prevent organ rejection following allogeneic transplantation, particularly in kidney, liver, and heart transplant patients. It works by selectively inhibiting T-lymphocyte activation, thereby suppressing immune responses that can lead to graft rejection. Due to its targeted immunomodulatory action, cyclosporine plays a critical role in transplant medicine.
Cyclosporine exerts its effect by inhibiting calcineurin, which blocks the transcription of interleukin-2 and other cytokines essential for T-cell activation. Due to its narrow therapeutic index, treatment requires careful dosing, therapeutic drug monitoring, and regular assessment of renal function and other safety parameters. Cyclosporine remains a cornerstone therapy in immunosuppressive treatment protocols worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing